Pan the man
10-03
$Regeneron Pharmaceuticals(REGN)$ 

辉瑞与特朗普政府的协议释放了一个信号:在美国市场,药企需要通过“降价换市场”的方式适应新政,但能率先达成协议的公司,反而能获得政策庇护和投资者信心。

在这一趋势下,Regeneron (REGN) 兼具强劲研发能力、核心药物护城河、与政府合作基础和稳健财务表现,极具投资价值。

REGN
10-03 01:30
USRegeneron Pharmaceuticals
SidePrice | FilledRealized P&L
Buy
Open
599.94
0
--
Closed
Regeneron Pharmaceuticals
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment